# The Response Draft Scored Against What FDA Rejected Before

**Niche:** [[niches/pharmaceutical-manufacturers/fda-inspection-483-response/profile|FDA Inspection Readiness & Form 483 Response]]
**Industry:** [[industries/pharmaceutical-manufacturers|Pharmaceutical Manufacturers]]
**Type:** Build (Greenfield Opportunity)
**One-liner:** Inspection-based warning letters tell a firm, in writing, why its 483 response was inadequate, and nobody uses that public archive to check a response before it is sent.
**Tags:** #bert #large-language-models #k-nearest-neighbors #word-embeddings #evaluation-metrics #compliance #quick-win
**Contested on:** Every serious competitor in this niche is fighting to answer an FDA Form 483 so that the agency judges the corrective actions adequate, and whoever closes the highest share of 483s without a warning letter takes the account.

## The Problem
A site has 15 business days to answer a 483 in a way FDA will accept. The response is drafted by QA and consultants from experience. Warning letters routinely quote the firm's own response and explain why it fell short: a root cause limited to one batch, no review of other products, retraining as the only action, no effectiveness check. That reasoning is public and repetitive, and it is not used as a test set.

## Why Nobody Has Built This
Consultancies treat their judgement as the product, and inspection-intelligence vendors sell search over documents rather than drafting. Firms rarely share their own responses, so success cases are scarce; the public record is mostly of failures.

## What to Build
Classify each observation by CFR section and quality system, retrieve the warning-letter passages where FDA assessed responses to comparable observations, check the site's QMS for the systemic scope an investigator will ask about, and draft a response and CAPA plan scored against the March 2026 draft guidance's elements and FDA's past objections. It can be demonstrated from public data alone (warning letters, the FY2025 observation spreadsheet with 2,837 drug citations, Data Dashboard citations); production value comes from joining the site's own deviation and CAPA history.

## Target Customer
Heads of quality at sites facing an inspection, especially foreign sites and small US makers without a standing remediation budget.

## Impact If Built
Avoiding one warning letter spares a site months of remediation spend, delayed approvals of pending applications and, for foreign sites, the risk of an import alert, a cost commonly $1–10M (estimate).
